– 6 Oral Presentations and 28 Posters Across HDV, HCV, HBV, NASH and PSC Highlight Progress and Gilead’s Leadership in Addressing Unmet Needs for People Affected by Liver Disease. | June 14, 2023
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
New Oral Pellet Formulation Enables Treatment in Early Childhood with Pangenotypic, Panfibrotic Regimen – Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration has approved an expansion of the pediatric indication of Epclusa ® for the treatment of chronic hepatitis C virus to now include children as young as 3 years of age, regardless of HCV genotype or liver disease severity. The FDA .